The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksUpdated•Originally published 21 April 2026•Updated 22 April 2026•

1 min read

Boston Scientific Beats Q1 Estimates but Issues Cautious Full-Year Guidance

Key Facts

1Stifel lowered its price target for Boston Scientific (BSX) to $85 from $90 while maintaining a Buy rating.

2The adjustment is based on a review of electrophysiology hospital-purchasing data and recent company commentary.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: Updated the story to include Q1 earnings and revenue beats, while adding the new full-year guidance that missed analyst estimates.

Boston Scientific (BSX) reported robust Q1 results, with adjusted earnings per share reaching $0.80, slightly ahead of the $0.79 analyst consensus. Quarterly revenue climbed 11.6% year-over-year to $5.20 billion, surpassing estimates of $5.17 billion, bolstered by a 13.5% surge in Cardiovascular segment sales to $3.50 billion. However, the company issued a cautious full-year adjusted EPS guidance range of $3.34 to $3.41, placing the midpoint below the market consensus of $3.45. This financial update follows a recent price target revision by Stifel to $85, though the firm maintained its Buy rating. Investors are now weighing the company's strong top-line momentum against the softer-than-expected earnings outlook for the remainder of the year.